Ken Griffin’s Gain Therapeutics GANX Stock Holding History

Ken Griffin’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.3K	Buy	+24,900	New	+$54.2K	﹤0.01%	12413
2025 Q4	–	Sell	-373,558	Closed	-$997K	–	13147
2025 Q3	$661K	Buy	373,558 +211,742	+131%	+$357K	﹤0.01%	8469
2025 Q2	$291K	Buy	161,816 +142,797	+751%	+$264K	﹤0.01%	9883
2025 Q1	$36.3K	Buy	19,019 +7,407	+64%	+$16.4K	﹤0.01%	12628
2024 Q4	$25.1K	Buy	+11,612	New	+$23.3K	﹤0.01%	13026
2024 Q2	–	Sell	-4,223	Closed	-$15.9K	–	14671
2024 Q1	$15.9K	Sell	4,223 -61,171	-94%	-$254K	﹤0.01%	13157
2023 Q4	$214K	Buy	65,394 +19,518	+43%	+$54.3K	﹤0.01%	9829
2023 Q3	$148K	Buy	45,876 +9,629	+27%	+$36.5K	﹤0.01%	10376
2023 Q2	$162K	Buy	36,247 +18,800	+108%	+$91.8K	﹤0.01%	10210
2023 Q1	$84.1K	Buy	+17,447	New	+$71.3K	﹤0.01%	11498
2022 Q1	–	Sell	-13,029	Closed	-$70K	–	13939
2021 Q4	$70K	Buy	+13,029	New	+$89.9K	﹤0.01%	13026

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ken Griffin's GANX Position: Q1 2026 in Review

Ken Griffin opened a new position in Gain Therapeutics (GANX) in Q1 2026: 24,900 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #12413 among its holdings. This is a return to the name: Ken Griffin previously reported a position in GANX as recently as Q3 2025.

Ken Griffin first reported a position in GANX in Q4 2021 and has held it in 11 quarters since. The position peaked at $661K in Q3 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Ken Griffin held 24,900 shares of Gain Therapeutics worth $48.3K as of Q1 2026.
Gain Therapeutics was a new Ken Griffin position in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12413 holding.
Ken Griffin first reported a position in Gain Therapeutics in Q4 2021 and has held it in 11 quarters since.
Ken Griffin's Gain Therapeutics position peaked at $661K in Q3 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.